• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by 4D pharma plc (Amendment)

    2/3/22 10:39:38 AM ET
    $LBPS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LBPS alert in real time by email
    SC 13G/A 1 tm225342d1_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Amendment No. 1)*

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO §240.13d-2

     

    4D Pharma, Plc.
    (Name of Issuer)

     

    Ordinary Shares, nominal value £0.0025 per Share

    (Title of Class of Securities)

     

    35085K109**
    (CUSIP Number)

     

            February 2, 2022        

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1 (b)

     

      x Rule 13d-1 (c)

     

      ¨ Rule 13d-1 (d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    1

    NAME OF REPORTING PERSON
    South Ocean Capital Management, LLC

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨
    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION
    Florida

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5

    SOLE VOTING POWER
    3,700,000

     

    6

    SHARED VOTING POWER
    -0-

     

    7

    SOLE DISPOSITIVE POWER
    3,700,000

     

    8

    SHARED DISPOSITIVE POWER
    -0-

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    3,700,000

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    2.05%

     

    12

    TYPE OF REPORTING PERSON*
    CO

     

           

     

     

     

     

    1

    NAME OF REPORTING PERSON
    Nemean Asset Management, LLC

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨
    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION
    Florida

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5

    SOLE VOTING POWER
    5,905,552

     

    6

    SHARED VOTING POWER
    -0-

     

    7

    SOLE DISPOSITIVE POWER
    5,905,552

     

    8

    SHARED DISPOSITIVE POWER
    -0-

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    5,905,552

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    3.28%

     

    12

    TYPE OF REPORTING PERSON*
    CO

     

           

     

     

     

     

    1

    NAME OF REPORTING PERSON
    South Ocean Capital, LLC

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨
    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION
    Florida

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5

    SOLE VOTING POWER
    612,880

     

    6

    SHARED VOTING POWER
    -0-

     

    7

    SOLE DISPOSITIVE POWER
    612,880

     

    8

    SHARED DISPOSITIVE POWER
    -0-

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    612,880

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    0.34%

     

    12

    TYPE OF REPORTING PERSON*
    CO

     

           

     

     

     

     

    1

    NAME OF REPORTING PERSON
    Steven M. Oliveira

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨
    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION
    U.S.A.

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5

    SOLE VOTING POWER
    10,218,432

     

    6

    SHARED VOTING POWER
    -0-

     

    7

    SOLE DISPOSITIVE POWER

    10,218,432

     

    8

    SHARED DISPOSITIVE POWER
    -0-

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    5.67%

     

    12

    TYPE OF REPORTING PERSON*
    CO

     

           

     

     

     

     

    1

    NAME OF REPORTING PERSON
    IRA financial trust FBO Steven M. Oliveira Roth IRA

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨
    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION
    U.S.A.

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5

    SOLE VOTING POWER
    9,605,552

     

    6

    SHARED VOTING POWER
    -0-

     

    7

    SOLE DISPOSITIVE POWER
    9,605,552

     

    8

    SHARED DISPOSITIVE POWER
    -0-

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    -0-

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    5.33%

     

    12

    TYPE OF REPORTING PERSON*
    OO

     

           

     

     

     

     

    Item 1.

     

      (a) Name of Issuer: 4D Pharma Plc, a corporation organized under the laws of England and Wales (the “Company”)

     

      (b) Address of Issuer's Principal Executive Offices:

     

    Item 2.

     

      (a) Name of Person Filing:

    South Ocean Capital Management, LLC owned by IRA financial trust FBO Steven M. Oliveira Roth IRA and managed by Steven M. Oliveira

    Nemean Asset Management, LLC, owned by IRA financial trust FBO Steven M. Oliveira Roth IRA and managed by Steven M. Oliveira

    South Ocean Capital, LLC, managed by Steven M. Oliveira and owned by Oliveira Family 2018 Delaware Trust and Bernadette Oliveira 2018 Delaware Trust

    IRA financial trust FBO Steven M. Oliveira Roth IRA

    Steven M. Oliveira

     

      (b) Address of Principal Business Office or if none, Residence:

     

    The address for these entities/individual is:

    c/o Steven M. Oliveira

    225 Via Palacio

    Palm Beach Gardens, FL 33418

     

      (c) Citizenship: South Ocean Capital Management, LLC – Florida
         

    Nemean Asset Management, LLC – Florida

    South Ocean Capital, LLC - Florida

    IRA financial trust FBO Steven M. Oliveira Roth IRA and Steven M. Oliveira – U.S.A.

     

      (d) Title of Class of Securities:  Ordinary shares, nominal value £0.0025 per share

     

      (e) CUSIP Number: 35085K109

     

    Item 3. Not Applicable

     

    Item 4. Ownership.

     

      (a) Amount Beneficially Owned:

     

    All information is as of February 2, 2022

     

    South Ocean Capital Management, LLC – 3,700,000 shares.

     

    Nemean Asset Management, LLC – 5,905,552 shares

     

    South Ocean Capital, LLC – 612,880 shares

     

    Steven Oliveira – 10,218,432 shares. Consists of securities owned by South Ocean Capital Management, LLC, Nemean Asset Management, LLC and South Ocean Capital, LLC

     

    IRA financial trust FBO Steven M. Oliveira Roth IRA – 9,605,552 shares. Consists of securities owned by South Ocean Capital Management, LLC and Nemean Asset Management, LLC

     

     

     

     

    Steven Oliveira has voting and dispositive power over the securities owned by South Ocean Capital Management, LLC, Nemean Asset Management, LLC, South Ocean Capital, LLC and IRA financial trust FBO Steven M. Oliveira Roth IRA

     

      (b) Percent of Class:

     

    South Ocean Capital Management – 2.05%

     

    Nemean Asset Management, LLC – 3.28%

     

    South Ocean Capital, LLC – 0.34%

     

    IRA financial trust FBO Steven M. Oliveira Roth IRA – 5.33%

     

    Steven Oliveira – 5.67%

     

    The foregoing percentages are based upon 180,300,966 Ordinary Shares outstanding as of March 26, 2021 as disclosed in the Issuer’s Form 20-F filed with the SEC on April 2, 2021.

     

      (c) Number of shares as to which such person has:

     

      (i) sole power to vote or to direct the vote:

     

    South Ocean Capital Management, LLC – 3,700,000 shares.

     

    Nemean Asset Management, LLC – 5,905,552 shares

     

    South Ocean Capital, LLC – 612,880 shares

     

    Steven Oliveira – 10,218,432 shares. Consists of securities owned by South Ocean Capital Management, LLC, Nemean Asset Management, LLC and South Ocean Capital, LLC

     

    IRA financial trust FBO Steven M. Oliveira Roth IRA – 9,605,552 shares. Consists of securities owned by South Ocean Capital Management, LLC and Nemean Asset Management, LLC

     

     

      (ii) shared power to vote or to direct the vote:

     

    South Ocean Capital Management, LLC – 0 shares.

     

    Nemean Asset Management, LLC – 0 shares

     

    South Ocean Capital, LLC – 0 shares

     

    Steven Oliveira – 0 shares

     

    IRA financial trust FBO Steven M. Oliveira Roth IRA – 0 shares

     

      (iii) sole power to dispose or to direct the disposition of:

     

     South Ocean Capital Management, LLC – 3,700,000 shares.

     

    Nemean Asset Management, LLC – 5,905,552 shares

     

    South Ocean Capital, LLC – 612,880 shares

     

    Steven Oliveira – 10,218,432 shares. Consists of securities owned by South Ocean Capital Management, LLC, Nemean Asset Management, LLC and South Ocean Capital, LLC

     

     

     

     

    IRA financial trust FBO Steven M. Oliveira Roth IRA – 9,605,552 shares. Consists of securities owned by South Ocean Capital Management, LLC and Nemean Asset Management, LLC

     

      (iv) shared power to dispose or to direct the disposition of:

     

    South Ocean Capital Management, LLC – 0 shares.

     

    Nemean Asset Management, LLC – 0 shares

     

    South Ocean Capital, LLC – 0 shares

     

    Steven Oliveira – 0 shares

     

    IRA financial trust FBO Steven M. Oliveira Roth IRA – 0 shares

     

    Item 5.

    Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial  owner of more than five percent of the class of securities, check the following [ ]. Not Applicable

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person: Not Applicable

     

    Item 7. Identification and Classification of Subsidiary Which Acquired the Securities: Not Applicable

     

    Item 8. Identification and Classification of Members of the Group: Not Applicable

     

    Item 9. Notice of Dissolution of Group: Not Applicable

     

    Item 10. Certifications: Not Applicable

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 3, 2022

     

     

      SOUTH OCEAN CAPITAL MANAGEMENT, LLC
         
         
      By: /s/ Steven Oliveira
        Name:  Steven Oliveira
        Title:    Authorized Signatory
         
       NEMEAN ASSET MANAGEMENT, LLC
         
         
       By: /s/ Steven Oliveira
        Name: Steven Oliveira
        Title:  Authorized Signatory
         
      SOUTH OCEAN CAPITAL, LLC
         
         
      By: /s/ Steven Oliveira
        Name:  Steven Oliveira
        Title:  Authorized Signatory
         
      IRA FINANCIAL TRUST FBO STEVEN M. OLIVEIRA ROTH IRA
         
         
        /s/ Steven Oliveira
        Steven Oliveira
         
         
        /s/ Steven Oliveira
        Steven Oliveira

     

     

     

    Get the next $LBPS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LBPS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LBPS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 4D pharma plc ("4D pharma") Receives Notice of Delisting From Nasdaq

      4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that on June 27, 2022, it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that in accordance with Listing Rules 5101, 5110(b), and IM-5101-1, Nasdaq Staff (the "Staff") has determined that 4D pharma's securities will be delisted from The Nasdaq Stock Market. Accordingly, trading of 4D pharma's LBPS will be suspended at the opening of business on July 7, 2022, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove 4D pharma's secur

      6/28/22 1:50:00 PM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Update on Suspension of Trading

      4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, provides an update to the announcement released earlier today regarding the Company's request for an immediate suspension of trading in the Company's ordinary shares on AIM which took effect from 12.30 p.m. (London). On 29 July 2021, the Company announced that it had agreed a senior secured credit facility (the "Facility") for up to US$30m with Oxford Finance LLC ("Oxford"), with an initial tranche of US$12.5 million drawn at closing and further tranches available dependent on the achievement of certain mileston

      6/24/22 2:41:00 PM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

      - Study to assess safety of MRx0518 with BAVENCIO and effect on progression-free survival at 6 months - Study sites are open for patient enrolment 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced the presentation of a trial in progress poster from the Phase II clinical trial of MRx0518 in combination with BAVENCIO® (avelumab), a PD-L1 blocking antibody, as a first-line maintenance therapy for patients with unresectable locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy, a

      5/26/22 5:30:00 PM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LBPS
    Leadership Updates

    Live Leadership Updates

    See more
    • 4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022

      4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today reported financial results for the full year ending December 31, 2021 and highlighted its key corporate objectives for 2022. "2021 was a productive year for 4D pharma. We reported promising signals in the clinic from our lead candidates in immuno-oncology and inflammatory disease, and entered into our second clinical collaboration in oncology, further validating the potential for single strain Live Biotherapeutics to treat systemic disease and the MicroRx platform. Additionally, we completed the merger wit

      3/31/22 5:27:00 PM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LBPS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by 4D pharma plc (Amendment)

      SC 13G/A - 4D Pharma PLC (0001830162) (Subject)

      3/2/22 5:24:43 PM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 4D pharma plc

      SC 13G - 4D Pharma PLC (0001830162) (Subject)

      2/28/22 4:17:17 PM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 4D pharma plc

      SC 13G - 4D Pharma PLC (0001830162) (Subject)

      2/25/22 3:52:23 PM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LBPS
    SEC Filings

    See more
    • SEC Form 6-K filed by 4D pharma plc

      6-K - 4D Pharma PLC (0001830162) (Filer)

      1/3/23 12:09:22 PM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by 4D pharma plc

      6-K - 4D Pharma PLC (0001830162) (Filer)

      11/18/22 2:58:44 PM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by 4D pharma plc

      6-K - 4D Pharma PLC (0001830162) (Filer)

      11/15/22 1:53:49 PM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LBPS
    Financials

    Live finance-specific insights

    See more
    • 4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma

      - Primary Efficacy Endpoint Met Early in Renal Cell Carcinoma Group in Part B of Study - Company to Host Conference Call and Webcast Today March 23, 10:00 am EST (2:00 pm GMT) 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that in Part B of its signal finding study of MRx0518 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with solid tumors that have progressed on a prior immune checkpoint inhibitor (ICI), the renal cell carcinoma (RCC) group has met its primary efficacy endpoint ahead of enrollment complet

      3/23/22 7:00:00 AM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 4D pharma Announces Additional Positive Data From Part A of the Phase I/II Trial Of MRx-4DP0004 For the Treatment of Asthma

      - Part A of the trial achieved the primary endpoint of safety and tolerability - Multiple secondary endpoints show positive trends in improving asthma control, supporting progression into Part B of the Phase I/II trial - Company to host conference call and webcast to discuss results today at 08:00 a.m. ET (1:00 p.m. GMT) 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces additional clinical data from Part A of its Phase I/II trial of MRx-4DP0004, an orally-delivered single strain Live Biotherapeutic being developed for the treatment of asthma.

      1/27/22 7:00:00 AM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care